Currently, the clinical translation of GPR17‐targeted therapies is hampered by the lack of detailed studies investigating the spatiotemporal distribution of GPR17‐expressing cells in the brains of human ischaemic stroke cases and the possible correlation with disease progression and neighbouring glial cell reactivity. This evidence concerns the gene GPR17 and ischemic stroke.